Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Cash & Current Investments: 2021-2024

Historic Cash & Current Investments for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $160,157.

  • ProQR Therapeutics N.V's Cash & Current Investments rose 127102.22% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.4 million, marking a year-over-year decrease of 2.22%. This contributed to the annual value of $160,157 for FY2024, which is 24.17% up from last year.
  • According to the latest figures from FY2024, ProQR Therapeutics N.V's Cash & Current Investments is $160,157, which was up 24.17% from $128,980 recorded in FY2023.
  • In the past 5 years, ProQR Therapeutics N.V's Cash & Current Investments ranged from a high of $226.6 million in FY2021 and a low of $128,980 during FY2023.
  • In the last 3 years, ProQR Therapeutics N.V's Cash & Current Investments had a median value of $160,157 in 2024 and averaged $32.8 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 99.87% in 2023, then climbed by 24.17% in 2024.
  • Yearly analysis of 4 years shows ProQR Therapeutics N.V's Cash & Current Investments stood at $226.6 million in 2021, then plummeted by 56.77% to $98.0 million in 2022, then slumped by 99.87% to $128,980 in 2023, then climbed by 24.17% to $160,157 in 2024.